Bicocca Open Archive

Logo unimib boa
PUOTI, MASSIMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.620
EU - Europa 5.049
AS - Asia 3.419
SA - Sud America 271
AF - Africa 48
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 4
Totale 16.417
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.488
SG - Singapore 1.746
RU - Federazione Russa 1.462
HK - Hong Kong 988
IT - Italia 879
IE - Irlanda 765
SE - Svezia 702
DE - Germania 541
CN - Cina 310
BR - Brasile 246
AT - Austria 178
ID - Indonesia 151
GB - Regno Unito 140
UA - Ucraina 107
CA - Canada 94
FI - Finlandia 67
NL - Olanda 62
VN - Vietnam 60
FR - Francia 47
IN - India 41
TR - Turchia 36
MX - Messico 30
CZ - Repubblica Ceca 18
ES - Italia 17
IR - Iran 15
ZA - Sudafrica 14
JP - Giappone 13
DK - Danimarca 11
AR - Argentina 10
BE - Belgio 10
PL - Polonia 9
PH - Filippine 8
BD - Bangladesh 7
ET - Etiopia 7
EG - Egitto 5
GR - Grecia 5
IQ - Iraq 5
KR - Corea 5
MU - Mauritius 5
PK - Pakistan 5
BG - Bulgaria 4
CL - Cile 4
IL - Israele 4
UZ - Uzbekistan 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AU - Australia 3
BO - Bolivia 3
CO - Colombia 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
EE - Estonia 3
GH - Ghana 3
HR - Croazia 3
JO - Giordania 3
NZ - Nuova Zelanda 3
SN - Senegal 3
AL - Albania 2
CH - Svizzera 2
CY - Cipro 2
EC - Ecuador 2
KZ - Kazakistan 2
LT - Lituania 2
MA - Marocco 2
MK - Macedonia 2
NG - Nigeria 2
OM - Oman 2
PE - Perù 2
PT - Portogallo 2
RO - Romania 2
TN - Tunisia 2
UG - Uganda 2
AM - Armenia 1
AZ - Azerbaigian 1
BY - Bielorussia 1
CG - Congo 1
EU - Europa 1
GE - Georgia 1
HU - Ungheria 1
IM - Isola di Man 1
KE - Kenya 1
KG - Kirghizistan 1
KH - Cambogia 1
LB - Libano 1
LU - Lussemburgo 1
MD - Moldavia 1
PA - Panama 1
PS - Palestinian Territory 1
SA - Arabia Saudita 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TM - Turkmenistan 1
TW - Taiwan 1
VE - Venezuela 1
ZM - Zambia 1
Totale 16.417
Salva come PNG Salva come JPEG
Città #
Singapore 1.272
Ann Arbor 1.097
Hong Kong 987
Dublin 756
Fairfield 593
Chandler 479
Houston 396
New York 396
Woodbridge 384
Princeton 381
Ashburn 346
Frankfurt am Main 334
Santa Clara 317
Wilmington 282
Milan 226
Seattle 220
Cambridge 196
Altamura 193
Lawrence 187
Jakarta 148
Jacksonville 111
San Diego 108
Vienna 106
Dearborn 103
Nuremberg 90
Moscow 87
Shanghai 69
Andover 64
Beijing 45
Dong Ket 45
London 43
Rome 43
Nanjing 40
Toronto 35
Los Angeles 31
Falls Church 30
Lachine 28
Helsinki 26
Hangzhou 24
Norwalk 22
Guangzhou 21
Fremont 20
São Paulo 20
Boardman 19
Cuauhtémoc 17
Pune 15
Chicago 14
Council Bluffs 14
Lappeenranta 13
Florence 12
Olomouc 12
The Dalles 12
Ottawa 11
Redmond 11
Shenyang 11
Tianjin 11
Turin 11
Washington 11
Brussels 10
Dallas 10
Madrid 10
Tokyo 10
Hebei 9
Jinan 9
Kilburn 9
Munich 9
San Mateo 9
Curitiba 8
Hyderabad 8
Lissone 8
Bergamo 7
Manassas 7
Mumbai 7
Salvador 7
Amsterdam 6
Buffalo 6
Cologno Monzese 6
Desio 6
Hounslow 6
Mountain View 6
Nanchang 6
Naples 6
Rio de Janeiro 6
Ancona 5
Bologna 5
Brno 5
Carate Brianza 5
Como 5
Groningen 5
Leawood 5
Parma 5
Uberlândia 5
Winnipeg 5
Athens 4
Belo Horizonte 4
Bolzano 4
Bovisio Masciago 4
Campinas 4
Chengdu 4
Ho Chi Minh City 4
Totale 10.864
Salva come PNG Salva come JPEG
Nome #
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 221
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 212
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 204
Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: Results from the Icona Foundation study 203
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort 193
Characteristics and Clinical Implications of Carbapenemase-Producing Klebsiella pneumoniae Colonization and Infection, Italy 192
Estimating minimum adult HIV prevalence: A cross-sectional study to assess the characteristics of people living with HIV in Italy 182
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 180
Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: Results from a large multicentre observational prospective cohort (SCOLTA) 176
Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study 172
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure 172
Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection: Results of an Italian compassionate use program 161
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 161
Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study 160
Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy 159
Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis c coinfection: Data from the ICONA foundation cohort 157
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 156
ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients 150
Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients 145
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 143
24 HOUR ARTERIAL DISTENSIBILITY IS RELATED WITH ABPM NON-DIPPING PATTERN IN HIVPOSITIVE PATIENTS 141
Successful pre- and posttransplant sofosbuvir-based anti-hepatitis C virus treatment in persons living with human immunodeficiency virus infection 137
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C 135
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 134
Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013 130
24-Hour Blood Pressure Monitoring Patterns in HIV-Positive Patients and its Relationship with Arterial Distensibility 130
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 128
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons 126
Risk of severe non AIDS events is increased among patients unable to increase their CD4 + T-cell counts >200+/μl despite effective HAART 125
Mild Course of SARS-CoV-2 Infection in a Liver Transplant Recipient Undergoing Plasma Exchange and Defibrotide for Acute Graft Rejection 123
Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy 122
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 120
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 119
Factors Influencing Depression Endpoints Research (FINDER): Baseline results of Italian patients with depression 117
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011 114
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014 112
HIV-positive to HIV-positive liver transplantation: To be continued 111
COVID-19 in liver transplant candidates: Pretransplant and post-transplant outcomes - An ELITA/ELTR multicentre cohort study 111
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 108
Impact of immunosuppressive therapy on the severity of COVID-19 in solid organ transplant recipients 108
Clinical outcome in solid organ transplant recipients with COVID-19: A single-center experience 106
Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: A longitudinal study 103
24-hours arterial distensibility is related with ABPM non-dipping pattern in HIV-positive patients 101
Trends in all-cause mortality of hospitalized patients due to SARS-CoV-2 infection from a monocentric cohort in Milan (Lombardy, Italy) 99
An update on integrase inhibitors: New opportunities for a personalized therapy?: The NEXTaim Project 98
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 97
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination 94
Sustained virological response with 16-week glecaprevir/pibrentasvir after failure to sofosbuvir/velpatasvir in post-transplant severe HCV recurrence in HIV 93
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C 93
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 92
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 91
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials 90
HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects from the ICONA Italian Cohort of HIV-Infected Patients 89
Association between markers of hepatitis B virus infection and risk of virological rebound in people with HIV receiving antiretroviral therapy 87
Home-based COVID 19 management: A consensus document from Italian general medical practitioners and hospital consultants in the Lombardy region (Italy) 87
SARS-CoV-2 RNA in plasma samples of COVID-19 affected individuals: a cross-sectional proof-of-concept study 87
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 87
HEFFICON: HIV effectiveness Italian conference 86
What is the impact of SARS-CoV-2 pandemic on antimicrobial stewardship programs (ASPs)? The results of a survey among a regional network of infectious disease centres 83
Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress? 80
Single-center outbreak of Pneumocystis jirovecii pneumonia in heart transplant recipients 79
Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a decade 79
Neurological manifestations in patients hospitalized with COVID-19: A retrospective analysis from a large cohort in Northern Italy 79
Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV 78
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 77
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: Results from the Italian EPOKA-MASTER cohort 77
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients 76
Management of infections pre- and post-liver transplantation: report of an AISF consensus conference 76
Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: Results from the EPOKA-MASTER cohort 75
Corrigendum to “Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV” [J Hepatol 68 (2018) 33–41](S0168827817322596)(10.1016/j.jhep.2017.08.019) 74
The use of molecular assays in the management of viral hepatitis 73
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 72
Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients with Lymphoproliferative Disorders on BTKi 71
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 71
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 71
Cerebral Infectious Opportunistic Lesions in a Patient with Acute Myeloid Leukaemia: The Challenge of Diagnosis and Clinical Management 70
Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis 70
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting 70
Risk factors and clinical characteristics associated with hospitalization for community-acquired bacterial pneumonia in HIV-positive patients according to the presence of liver cirrhosis 68
Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. 68
Sex differences in electrolyte imbalances caused by SARS-CoV-2: A cross-sectional study 68
Prophylaxis and treatment of hepatitis B in immunocompromised patients 68
Surge of Mpox cases in Lombardy region, Italy, October 2023 - January 2024 67
CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: A multinational, multicohort European study 67
Successful recovery from severe COVID-19 pneumonia after kidney transplantation: The interplay between immunosuppression and novel therapy including tocilizumab 66
Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study 66
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 66
Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data from the PRESTIGIO Registry 66
Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy 66
Multiple concomitanti infezioni opportunistiche e linfomi aggressivi in una persona con HIV/AIDS che non assumeva la terapia ant 65
Risk factors for community-acquired bacterial meningitis: men who have sex with men (MSM) as a population at risk for meningococcal nasopharyngeal carriage 64
Development and validation of a prediction model for tocilizumab failure in hospitalized patients with SARS-CoV-2 infection 64
Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study 64
Detection and quantification of SARS-CoV-2 by droplet digital PCR in real-time PCR negative nasopharyngeal swabs from suspected COVID-19 patients 63
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? 62
Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV patients with cirrhosis 61
Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin in patients with chronic hepatitis C virus genotype 1 infection receiving opioid substitution therapy: A post hoc analysis of 12 clinical trials 61
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort 61
Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop 61
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort 60
Totale 10.553
Salva come PNG Salva come JPEG
Categoria #
all - tutte 94.727
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 94.727
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020129 0 0 0 0 0 0 0 0 0 0 89 40
2020/20211.907 64 114 89 102 117 113 125 389 267 156 204 167
2021/20221.849 73 108 269 174 85 120 44 273 125 101 89 388
2022/20232.624 467 752 231 174 113 433 24 140 162 24 71 33
2023/20242.584 55 63 79 70 344 598 443 55 295 48 101 433
2024/20256.316 515 1.157 430 379 661 339 413 214 897 1.264 47 0
Totale 17.372